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The passive administration  of antibody can result in both positive and  negative 
signals which regulate the immune response (1-3). Regulation of the immune response 
by antibody is dependent on the time between the administration of passive antibody 
relative to antigen (2). In view of these observations, Brystryn et al. (4) proposed that 
production of antibody is controlled via a  dynamic equilibrium among circulating 
antibody, antigen, and  antigen-antibody complexes. Thus, one would  predict  that 
both enhancement  (5)  and  suppression  (6)  of the immune response are dependent 
upon the ratio of antigen to antibody. 
It was shown that passively administered antibody can function independently of 
the  Fc  region  by  directly  masking  antigenic  determinants,  thus  inhibiting  their 
presentation  to  lymphocytes  (7,  8).  On  the  other  hand,  other  investigators  have 
provided  evidence  that  the  Fc  portion  of the  antibody  molecule  is  essential  for 
suppression  (9-14).  This controversy was  resolved by Hoffmann and  Kappler  (14) 
who  reported  that  when  high  concentrations  of passive  antibody  were  used,  the 
antigenic determinants were blocked independently of the Fc region, whereas with 
lower concentration of antibody the Fc portion was required. 
Although emphasis has been placed on the suppressive arm of passively adminis- 
tered antibody, enhancement has also been reported in the literature. Such enhance- 
ment has been shown with both particulate (15,  16) and soluble antigens (17-19) in 
mice. The direct activation of normal lymphocytes by antigen-antibody complexes 
have produced conflicting results. Block-Shtacher et al. (20) and M611er (21) reported 
that antigen-antibody complexes could stimulate proliferation in human peripheral 
blood lymphocytes. Stimulation  of murine  lymphocytes by antigen-antibody com- 
plexes has been shown to occur by some investigators (3) but not others (12, 22, 23). 
Fc  fragments  derived  from  mammalian  immunoglobulin  .(Ig)  (3,  24-27)  and 
aggregated human gamma globulin  (24, 28), in addition  to antigen-antibody com- 
plexes (3), are known to be potent activators of murine bone marrow-derived (B) cells 
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in that they have the capacity to induce B cells to proliferate and undergo polyclonal 
activation. 
The ability of Fc fragments to mediate a  variety of biological functions prompted 
investigation for their ability to modulate an antibody response. The studies in this 
report demonstrate that Fc fragments can act as potent in vivo or in vitro adjuvants, 
and the conditions necessary for obtaining the enhanced responses are described. 
Materials  and  Methods 
Animals.  Male mice of the C57BL/6J  and A/J strains were obtained from The Jackson 
Laboratory (Bar Harbor, Maine). All mice were between 8 and  14 wk of age when used. 
Priming for  Seconda~  In  Vitro Antibody  Response.  Mice  were  injected  with  0.1  ml  of  10% 
suspension of sheep erythrocytes (SRBC) 1 (Colorado Serum Co., Denver, Colo.) intraperitone- 
ally. 6-8 wk after priming, they were boosted intraperitoneally with the same dose of SRBC 
and were used 7 d later. 
Tolerization.  Mice were tolerized to aggregated human gamma globulin (HGG) (AHGG) as 
described in Doyle et  al.  (29).  Pooled HGG was obtained as Cohn  fraction II through  the 
courtesy of the American Red Cross National Fractionation Center (with the partial support of 
National Institute of Health grant HE-138801)  and was purified by DEAE-cellulose chroma- 
tography with 0.01 M  phosphate buffer, pH 8.0, used as the eluent. The HGG was centrifuged 
at 150,000 g for 150 min at 4°C in a swinging bucket sw 50.1 rotor (Beckman Instruments, Inc., 
Spinco Div., Palo Alto, Calif.). The upper quarter of the solution was removed, and 2.5 mg in 
0.5 ml was immediately injected intraperitoneally. 30 d posttolerization a portion of the mice 
were  tested for tolerance by immunizing with  400 #g  heat-aggregated HGG  intravenously 
followed by another 400-#g injection 10 d later. The spleens were removed 4 d after the second 
injection and  assayed for plaque-forming cells (PFC)  to  HGG.  A  tolerized, nonimmunized 
group was used for experiments involving the use of Fc as an adjuvant. 
Preparation of Fc Fragments 
HUMAN.  A  human  IgGx myeloma protein (Fi) was a  gift from Dr.  Hans L. Spiegelberg, 
Scripps Clinic and Research Foundation, La Jolla, Calif. The IgG1 was purified by ammonium 
sulfate  fractionation  followed by  DEAE-cellulose chromatography  with  0.01  M  phosphate 
buffer, pH 8, used as the eluent. 
Fc fragments were obtained by digestion of IgGx with  papain  (Sigma Chemical Co.,  St. 
Louis, Mo.)  in  the  presence of L-cysteine (Sigma Chemical  Co.)  and  EDTA  (J.  T.  Baker 
Chemical Co., Phillipsburg, N. J.)  for 5 h  (30),  After digestion, the material was ehromato- 
graphed on Sephadex G-100 (Pharmaeia Fine Chemicals, Div. of Pharmaeia Inc., Piscataway, 
N. J.)  to remove any undigested IgG. The Fc and Fab fragments were then separated from 
each other by DEAE-cellulose chromatography (31). 
MURINE.  Mouse  gamma  globulin was  obtained  from  N.  L.  Cappel  Laboratories,  Inc., 
(Cochranville, Pa.). Fc fragments were prepared as described for HGG except a  2-h digestion 
was employed (24). 
Generation of Immune Responses 
IN vxvo RESPONSE TO StnC.  Mice, in groups of four to five, were given 0.1  ml of a  SRBC 
suspension intraperitoneally, followed immediately by saline, Fc, Fab, or IgG intravenously. 
The spleens were assessed for PFC to SRBC 5 d postimmunization. 
IN VITRO RESPONS~ TO SRBC.  Spleens were removed from primed and boosted, mice, and a 
single cell suspension was prepared by teasing the spleens apart with forceps into phosphate- 
buffered saline (0.001 M sodium phosphate, 0.15 M NaCI, pH 7.4). A modified Mishell-Dutton 
culture system was employed for the generation of antibody-producing cells (32).  Cells were 
suspended to a concentration of 6  ×  106/ml RPMI-1640  (Flow Laboratories, Inc., Rockville, 
1  Abbreviations used in th,s paper: AHGG, aggregated human gamma globulin; BRBC, burro erythrocytes; 
DHGG, deaggregated human gamma globulin; HGG, human gamma globulin; LPS, lipopolysaccharide; 
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Md.), supplemented with 2 mM L-glutamine, 1% BME vitamins (Grand Island Biological Co., 
Grand  Island,  N.  Y.),  100  U  penicillin,  100  #g  streptomycin  (Microbiological  Associates, 
Walkersville, Md.), 5 ×  10  -5 M 2-ME, 7.5% fetal calf serum (Grand Island Biological Co.), and 
0.5% fresh normal mouse serum. The spleen  cells ata concentration of 6  ×  105 along with 
various concentrations of SRBC and Fc, Fab, or IgG were cultured in 0.3-ml  final volume in 
flat-bottom microtiter plates (3040 Micro Test II; Falcon Labware, Div. of Becton,  Dickinson 
& Co., Oxnard, Calif.)  for 4 d at 37°C in 5% CO~. At the end of this time duplicate cultures 
were pooled and assessed for PFC to SRBC. 
PFC Assay.  PFC to HGG and SRBC were assayed by a  slide  modification of the Jerne 
plaque assay (33). For detection of PFC to HGG, burro erythrocytes (BRBC)  (Burley  Farms, 
San  Diego,  Calif.)  were conjugated with  BRBC-adsorbed Cohn  fraction II HGG by using 
water-soluble  carbodiimide (Story  Chemical Co., Muskegon, Mich.)  (34). Guinea pig serum 
(Pel-Freez  Biologicals  Inc.,  Rogers,  Ark.)  was  used  to  develop  the  direct  plaques  and  a 
combination  of guinea  pig  serum  and  rabbit  anti-mouse  immunoglobulin  to  develop  the 
indirect  plaques.  Only  indirect  PFC  were  determined  for HGG responses  because only  a 
minimal IgM response is obtained with this antigen. The number of IgG PFC were calculated 
using a correction factor for inhibition of the IgM PFC by the developing antiserum. Data are 
expressed as PFC/106 spleen cells :t: SE. Each experiment was performed a minimum of three 
times, and the experiments shown are representative of all the data. 
Results 
Enhancement of the Antibody Response by Fc Fragments.  To study whether Fc fragments 
derived from human Ig had the capacity to act as an adjuvant, the antibody response 
to  SRBC  was  investigated.  The  results  in  the  Fig.  1  indicate  Fc  fragments  have 
adjuvant properties when administered with antigen in vivo. The observed adjuvant 
effect  is  extremely  dependent  upon  the  dose  of antigen  employed.  The  greatest 
enhancement (~ 14-fold) of the anti-SRBC response occurred when a suboptimal dose 
of SRBC was used.  Moreover, when conditions were employed where the maximum 
anti-SRBC response was achieved, the addition of Fc fragments produced little or no 
enhancement (1,225 vs. 1,395 PFC). There was no polyclonal antibody response upon 
injection of Fc fragments alone. 
Because a dramatic increase in the in vivo anti-SRBC response was achieved with 
Fc  fragments,  experiments were conducted  to determine  if a  similar enhancement 
occurred  in  vitro.  The  addition  of Fc  fragments  with  SRBC  to  in  vitro  cultures 
resulted in a  pronounced enhancement of the IgM anti-SRBC response (Fig.  2).  An 
eightfold enhancement of the response occurred when Fc fragments were administered 
with  low  numbers  of  SRBC.  As  observed  with  the  in  vivo  response,  when  the 
maximum in vitro response was attained, there was virtually no measurable adjuvant 
effect (700 vs. 730 PFC). 
To ensure that the enhancement of the anti-SRBC response was indeed mediated 
by the Fc fragments and was not a result of the addition of extraneous protein to the 
system,  the  effects of Fab  fragments  and  intact  IgG on  the  in  vivo  and  in  vitro 
responses were assessed. The intact IgG and Fab fragments derived from this myeloma 
protein  did  not  increase  the  anti-SRBC  response above that  obtained  with  SRBC 
alone (Table I). On the other hand, the Fc fragments produced a significant increase 
in both the in vivo (approximately fivefold) and in  vitro (approximately eightfold) 
antibody responses. All experimentation described subsequently employed 0.1  ml of 
1% suspension of SRBC  (~2.5  ×  107)/mouse for in  vivo work and  I  ×  104 SRBC/ 
culture for in vitro studies. 
To determine if the addition of Fc to in vitro spleen cell cultures altered the peak 116  POTENTIATION  OF  ANTIBODY  RESPONSES  BY  Fc  FRAGMENTS 
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FIG.  1.  Enhancement of the primary in vivo anti-SRBC response with Fc fragments. Increasing 
numbers of SRBC even injected with 0.5 #g Fc (~) or alone (D). There were four to five mice/group 
and the experiment assayed on day 5. 
day of response to SRBC, kinetic experiments were performed. The response to SRBC 
was measured over a  5-d period, and the results show that  the anti-SRBC response 
peaked on day 4 of culture regardless of the presence or absence of Fc fragments in 
culture (Fig. 3). 
Concentration of Fc Fragments Needed for  Enhancement of the  Antibody Response.  To 
determine the optimal amount of Fc fragments needed to enhance the in vivo response 
various  doses  of Fc  were  injected with  a  constant  number  of SRBC.  The  results 
indicate  that  maximal  enhancement  of the  in  vivo anti-SRBC  response  occurred 
when 0.5 mg Fc was injected (Fig. 4, group III). The minimum dose of Fc tested (0.1 
mg) produced a significant adjuvant effect (12-fold), but was lower than 0.5 mg (17- 
fold). To ascertain the optimal concentration of Fc fragments needed to enhance the 
in vitro anti-SRBC response, different amounts of Fc were added with 1 x  104 SRBC 
to the cultures.  100 #g of Fc gave the greatest adjuvant effect (fivefold) (Fig. 5, group 
III)  with  both  lower  and  higher  amounts  being  approximately  equal  (twofold). 
Experimentation described subsequently employed 0.5 mg Fc/mouse and  100 #g Fc/ 
culture. 
Enhancement of the IgG Response by Fc Fragments.  The  above studies  describe  the 
enhancement of the secondary direct or IgM response to SRBC;  experiments were 
similarly conducted to ascertain if the IgG response could be boosted. The results in 
Table II indicate that the secondary in vitro IgG anti-SRBC response is enhanced by MORGAN,  WALKER,  THOMAN,  AND  WEIGLE 
800" 
700- 
600 
~- 500- 
evs 
ee. 
"~ 400- 
,~,, 
m  300" 
200- 
100-  ,..,~ 
i 
0 
¢]  IIJ 
|  ! 
103  104  5  104 
8RBCICulture 
117 
! 
105 
FIG.  2.  Enhancement of the secondary in vitro anti-SRBC response with Fc fragments. Increasing 
numbers of SRBC were added with 100 #g (n) or alone (~) to in vitro cultures. The response was 
measured on day 4. 
TABLE  I 
Enhancement of the In  Vivo and In  Vitro PFC Responses to SRBC by Fc 
Fragments in the Presence of Low Antigen Doses 
Stimulator  SRBC 
Anti-SRBC 
In vivo*  In vitro* 
PFC/IO  6 + SE 
--  -  <25  <2,.5 
--  +§  310 ±  18  106 ±  14 
Fell  -  <25  80 ±  2 
Fc  +  1,287 ±  127  858 ±  70 
Fahll  -  <25  <25 
Fab  +  430 4- 74  141  ±  31 
IgGll  -  <25  <25 
IgG  +  266 ±  95  193 ±  41 
* The response was measured 5 d after injection. 
The response was measured on day 4 of culture. 
§ For the in vivo experiment, mice received 0.1  ml of 1% SRBC. 
For the in vitro experiments, cultures received  1 ×  104 SRBC. 
j] In  vivo  experiment  mice  received  0.5  rag.  In  vitro  experiment  cultures 
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Fro.  3.  Kinetics of the in vitro anti-SRBC response. Spleen cells were cultured with 1 X 10  4 SRBC 
(O)  1 ×  lO  4 SRBC plus 100 ~g Fc (O), or lO0 ~g Fc only (A) and the response measured on day 3- 
5 of culture. 
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FIG.  4.  Increasing concentrations of Fc fragments were injected with a constant number of SRBC 
(0.1 ml of 1%) to determine the optimal concentration of Fc needed for enhancement of the in vivo 
anti-SRBC response. The response was measured on day 5. 
the  addition  of Fc  fragments  (fourfold).  The conditions  for obtaining  the  optimal 
adjuvant  effect of the  IgG response were  the  same as  the  IgM  response  (data  not 
shown). 
Effect of Fc Fragment Antigenicity  on the  In  Vivo Adjuvant Effect.  Because  human  Fc 
fragments are antigenic at the concentrations employed it was important to determine 
whether  the  observed  adjuvant  effect  was  a  result  of the  antigenicity  of the  Fc 
molecule. Mice were rendered tolerant (97% unresponsive) (data not shown) to HGG 
before use in the following experiments. When the tolerant mice were injected with 
Fc fragments and SRBC, the anti-SRBC response was enhanced (~ 17-fold) compared MORGAN, WALKER, THOMAN,  AND WEIGLE  119 
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Fro. 5.  Increasing concentrations of Fc fragments were added with a constant  number of SRBC 
(1 ×  10  4) to in vitro culture to determine the optimal concentration  of Fc needed for enhancement 
of the in vitro anti-SRBC response. The response was measured on day 4 of culture. 
TABLE II 
Enhancement of the In Vitro Secondary IgM and IgG Responses to SRBC with 
Fc Fragments 
Fc*  SRBC:]: 
Anti-SRBC 
IgM  IgG 
PFC/IO s + SE 
-  -  10:1=2  60::1=  19 
-  +  102  +  19  331 + 28 
+  -  81 +  16  90-'1-27 
+  +  670 + 37  1,272 ..i- 73 
* 100 #g Fc/cuhure. 
:~ 1 X 104 SRBC/culture. 
with  the level of normal control mice  (Table III, groups  III and  VII). As described 
previously, Fab fragments had no effect on the anti-SRBC response (groups IV and 
VIII). 
To delineate further the role of the antigenicity of the Fc molecule, Fc fragments 
were prepared from murine Ig and injected along with SRBC in mice. The murine Fc 
fragments were able to enhance the in vivo anti-SRBC response (sixfold) (Table IV, 
group  IV).  Intact  murine  IgG or  Fab  fragments  produced  no  significant  adjuvant 
effect  (Table IV,  groups  VI  and  VIII). These  results  indicate  that  homologous  Fc 
fragments possess adjuvant  properties, thus ruling out  the possibility that  the adju- 
vanticity of Fc fragments is related to antigenicity of the molecule. 
The  enhancement  of both  the  in  vivo and  in  vitro anti-SRBC  responses  ranged 
from  "-'4-fold to ~  17-fold, and  the experiments shown  are respresentat~ve of all the 
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TABLE  III 
Enhancement of an In  Vivo PFC Response to SRBC in Mice Tolerant to 
Human Gamma Globulin 
Group  Treatment*  Fc:[:  Fab§  SRBC~  Direct anti- 
SRBC 
PFC/IO  s ±  SE 
I  DHGG  -  -  +  <25 
II  DHGG  +  -  -  <25 
lit  DHGG  +  -  +  408 3= 6 
IV  DHGG  -  +  +  <25 
V  None  -  -  +  <25 
VI  None  +  -  -  <25 
VII  None  +  -  +  371  ±  48 
VIII  None  -  +  +  <25 
* Mice were given 2.5 mg deaggregated human  gamma  globulin (DHGG)  30 
d  previously. Mice were 97% unresponsive to HGG  challenge. 
Mice were injected with 0.5 mg Fc intravenously. 
§ Mice were injected with 0.5 mg Fab intravenously. 
]1 Mice were injected with 0.1 ml of 1% SRBC intraperitoneally. 
TABLE  IV 
Enhancement of an In  Vivo PFC Response to SRBC by Murine Fc Fragments 
Group  Fc*  Fab:]:  IgG§  SRBC u  Direct anti-SRBC 
PFC/IO  6 +  SE 
I  ....  <25 
II  ....  205 :t= 28 
III  +  -  -  -  <25 
IV  +  -  -  +  1,310 +  281 
V  -  +  -  -  <25 
VI  -  +  -  +  326 ±  75 
VII  -  -  +  -  <25 
VIII  -  -  +  +  270 :t: 61 
* 0.5 mg murine Fc given intravenously. 
0.5 mg murine Fab given intravenously. 
§ 0.5 mg murine IgG given intravenously. 
II 0.1  ml of 1% SRBC suspension given intraperitoneally. 
Discussion 
A model is described in this report for the enhancement of both in vivo and in vitro 
antibody responses by Fc fragments.  The injection of Fc fragments along with SRBC 
or the addition of Fc and SRBC to spleen cell cultures results in a dramatic increase 
in  the  number of both IgM and  IgG anti-SRBC  PFC.  The  Fc  fragment  adjuvant 
effect  is  a  result  of the  interaction  of spleen  cells  with  Fc  and  not  a  nonspecific 
stimulation by protein, as Fab fragments and intact IgG were not able to generate the 
heightened anti-SRBC responses. 
The Fc fragment-induced adjuvant effect was found to be dependent upon the dose 
of antigen injected or added to the in vitro cultures. The most pronounced increase in 
the anti-SRBC response occurs where suboptimal amounts of antigen are employed. 
The adjuvant effect decreases as the concentration of antigen increases, and when the 
optimal  amount  of  antigen  is  reached,  Fc  fragments  fail  to  affect  the  antibody MORGAN, WALKER, THOMAN, AND WEIGLE  121 
response. That antigen concentration apparently plays a critical role in the adjuvan- 
ticity of various agents has been suggested in the literature (35, 36). Sj6berg et al. (35) 
observed that the adjuvanticity of bacterial lipopolysaccharide (LPS) for a  primary 
in vitro response to SRBC occurred only when a low number of SRBC were added to 
culture. Moreover, Specter et al.  (36) found that the synthetic product N-acetylmu- 
ramyl-L-ananyl-O-isoglutamine (muramyl dipeptide) enhanced the immune respon- 
siveness  of normal  lymphocytes most  dramatically when  suboptimal  numbers  of 
SRBC were used. However, Amerding and Katz (37) showed that LPS enhances in 
vitro responses to SRBC over all antigen concentrations tested. The correlation of 
adjuvanticity with antigen dose is apparently dependent on a number of variables. 
That the cellular events involved in the polyclonai activity and their adjuvanticity 
are different is suggested by the difference in the kinetics of the two responses. This is 
concluded from the fact that the Fc fragment induced polyclonal response peaks on 
day 3 of culture (27), whereas the anti-SRBC response peaks on day 4. The addition 
of Fc fragments to the SRBC cultures does not alter the kinetics of the response. This 
observation agrees with those previously published (35), which show that when SRBC 
are added to LPS-treated spleen cell cultures, the anti-SRBC response is higher than 
in those cultures receiving only SRBC, but the overall kinetics of the response remain 
unaltered in the presence of LPS. 
Fc fragments derived from routine Ig are as potent an adjuvant as Fc prepared 
from heterologous Ig. This observation is very important when considering the use of 
such an adjuvant in the human model. An ideal adjuvant would be a substance which 
could potentiate the immune response but yet be nonantigenic itself. That antigenicity 
plays no part in the adjuvant effect is further substantiated by the fact that the anti- 
SRBC response of mice rendered tolerant to HGG is capable of being enhanced by 
human Fc fragments to the level of untreated control mice. 
The nature of the regulatory role(s)  of Fc fragments in the immune response is not 
clear at the present time. Although we have presented evidence indicating that Fc 
fragments  can  potentiate  the  immune  response,  data  exist  which  show  that  Fc 
fragments have the capacity to suppress an antibody response as well (3). These results 
are reminiscent of those dealing with immune complexes, where antibody responses 
are enhanced (5,  15-19)  as well as suppressed (6,  14). That homologous Fc fragments 
are capable of enhancing an antibody response lends credence to the idea that Fc 
fragments regulate the antibody response in a manner similar to immune complexes. 
Hoffmann and Kappler (14) postulated that antibody regulated the humoral immune 
response by affecting the cooperation between T cells and B cells by attaching antigen 
through its Fc fragment to the surface of cells which carry Fc receptors. Because Fc 
fragments affect B cells (3,  24-27),  T  cells (27),  and macrophages 26,  27),  multiple 
sites of regulation are possible.  The nature of the regulatory event(s)  and  the cell 
population(s) affected are the focl of another report.  ~ 
Summary 
Fc fragments derived from human and murine Ig were found to be potent adjuvants 
when administered with antigen. Both the in vivo and in vitro anti-sheep erythrocytes 
(SRBC) responses were significantly enhanced by Fc fragments. The adjuvant effect 
was shown to be extremely dependent upon the dose of antigen used, with the greatest 
2  Morgan,  E. L., M. L. Thoman,  S. M. Walker,  and W. O. Weigle. Manuscript  submitted  for publication. 122  POTENTIATION OF  ANTIBODY RESPONSES  BY Fc  FRAGMENTS 
enhancement  occurring  when  suboptimal  doses of antigen  are employed.  The anti- 
genicity of the Fc molecule was not  related  to its adjuvanticity  because homologous 
Fc  was  as  potent  an  adjuvant  as  heterologous  Fc.  Moreover,  human  Fc  fragments 
enhanced  anti-SRBC  responses  in  mice  which  were  tolerant  to  human  gamma 
globulin. 
The authors wish to thank Nancy Kantor for technical  excellence and  Mary Chalmers and 
Janet Kuhns for secretarial expertise. 
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